Regeneron Pharmaceuticals
REGN
1,331 hedge funds and large institutions have $98.9B invested in Regeneron Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 125 funds opening new positions, 545 increasing their positions, 428 reducing their positions, and 84 closing their positions.
49% more first-time investments, than exits
New positions opened: 125 | Existing positions closed: 84
27% more repeat investments, than reductions
Existing positions increased: 545 | Existing positions reduced: 428
16% more funds holding in top 10
Funds holding in top 10: 25 → 29 (+4)
11% more capital invested
Capital invested by funds: $89.2B → $98.9B (+$9.73B)
2% more funds holding
Funds holding: 1,309 → 1,331 (+22)
0.59% more ownership
Funds ownership: 86.29% → 86.89% (+0.59%)
30% less call options, than puts
Call options by funds: $1.09B | Put options by funds: $1.55B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$533M |
| 2 |
Goldman Sachs
New York
|
+$298M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$222M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$160M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$158M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$140M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$137M |
| 3 |
BlackRock
New York
|
-$119M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$107M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$86.5M |
REGN Hedge Fund Activity: Q2 2024 in Review
1,331 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2024, worth a combined $98.9B — up 11% from $89.2B a quarter earlier.
Buyers outnumbered sellers: 125 funds opened new REGN positions and 84 closed out — a net gain of 41 holders — while 545 added to existing stakes and 428 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $533M. The largest seller was Fidelity Investments, cutting an estimated $140M.
- 1,331 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2024, up from 1,309 in Q1 2024.
- Funds reported $98.9B of Regeneron Pharmaceuticals stock for Q2 2024, up 11% quarter-over-quarter.
- 125 funds opened new Regeneron Pharmaceuticals positions in Q2 2024 and 84 closed out, a net change of +41 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2024 was JP Morgan Chase, an estimated $533M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2024 was Fidelity Investments, an estimated $140M sold.
Based on aggregated 13F filings for Q2 2024.